You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》麥格理上調百濟神州(06160.HK)目標價至101.46元 評級「跑輸大市」
阿思達克 01-13 10:21
麥格理發表研究報告,指出百濟神州(06160.HK)最有價值的競爭力仍然是其交易能力,看到其最近與Novartis Pharma(諾華)達成另一項具里程碑意義的交易,公司將抗PD-1抗體百澤安(替雷利珠單抗)的許可銷售權授予諾華,授權區域包括在大中華區、韓國、東盟和澳洲以外的主要地區。

對於海外的試驗及適應症,百濟神州將資助正在進行的全球試驗,而諾華將為其領域的新試驗提供資金。對於聯合試驗,每家公司將自行付費並保留其專有產品進行任何聯合療法的全球權利。

該行將百濟神州的目標價由原來的95.76元上調至101.46元,但認為股價已提前反映最近公布的消息,投資評級「跑輸大市」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account